Point72 Asset Management
AGIO icon

Point72 Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Point72 Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$497K Buy
+14,700
New +$417K ﹤0.01% 3116

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Point72 Asset Management's AGIO Position: Q1 2026 in Review

Point72 Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 200,000 shares — an estimated $5.67M sold.

Point72 Asset Management first reported a position in AGIO in Q2 2014 and held it in 19 quarters. The position peaked at $33.2M in Q1 2018. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Point72 Asset Management reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 200,000 Agios Pharmaceuticals shares in Q1 2026, an estimated $5.67M.
  • Point72 Asset Management first reported a position in Agios Pharmaceuticals in Q2 2014 and held it in 19 quarters.
  • Point72 Asset Management's Agios Pharmaceuticals position peaked at $33.2M in Q1 2018.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.